Related Experiment Video

Updated: May 16, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Ocriplasmin for vitreoretinal diseases

Irena Tsui1, Carolyn K Pan, Ehsan Rahimy

  • 1Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA. itsui@jsei.ucla.edu

Journal of Biomedicine & Biotechnology
|November 30, 2012
PubMed

Insights

Ocriplasmin, a novel ophthalmic medication, effectively cleaves fibronectin and laminin at the vitreoretinal interface. Clinical trials show promising results for treating vitreoretinal diseases, potentially improving patient outcomes.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Pharmacology

Background:

  • Fibronectin and laminin are key proteins at the vitreoretinal interface.
  • These proteins are implicated in various vitreoretinal diseases.
  • Plasmin receptors play a crucial role in ocular tissue remodeling.

Purpose of the Study:

  • To evaluate the efficacy of ocriplasmin in cleaving fibronectin and laminin.
  • To assess the potential of ocriplasmin as a treatment for vitreoretinal diseases.
  • To investigate the impact of ocriplasmin on patient care for conditions like vitreomacular traction and macular hole.

Main Methods:

  • Clinical trials were conducted to study ocriplasmin.
  • Ocriplasmin's action on fibronectin and laminin was investigated.
  • Patient outcomes for specific vitreoretinal diseases were monitored.

Main Results:

  • Ocriplasmin demonstrated the ability to cleave fibronectin and laminin.
  • Clinical trials yielded promising results for ocriplasmin's therapeutic potential.
  • The medication showed potential in addressing vitreoretinal pathologies.

Conclusions:

  • Ocriplasmin is a novel ophthalmic medication targeting specific plasmin receptors in the eye.
  • Promising clinical trial results suggest ocriplasmin may significantly impact the management of vitreoretinal diseases.
  • Further research and application of ocriplasmin may lead to improved patient care.

More Related Videos

Intravitreal Injections in the Ovine Eye03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...